글로벌 운동실조증 시장 – 2029년까지의 산업 동향 및 예측

보고서 사용자 지정 보고서 사용자 지정 지금 구매 지금 구매 무료 샘플 보고서 무료 샘플 보고서
집 Pharmaceutical Global Ataxia Market
TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

글로벌 운동실조증 시장 – 2029년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Apr 2022
  • Global
  • 350 Pages
  • 테이블 수: 1177
  • 그림 수: 77
지금 구매 지금 구매

Global Ataxia Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
 2022 –2029
Diagram 시장 규모(기준 연도)
 USD 22,631.81 Thousand
Diagram 시장 규모(예측 연도)
 USD 36,900.18 Thousand
Diagram 연평균 성장률
 %
Diagram 주요 시장 플레이어
  • Novartis
  • Merck
  • Aurobindo Pharma
  • Pfizer
  • Sanofi

글로벌 운동실조 시장, 유형별( 척추소뇌성 운동실조, 운동실조-모세혈관확장증, 발작성 운동실조 및 기타(다발계통위축증(MSA))), 제품(치료 및 진단), 투여 형태(고체, 액체 및 기타), 투여 경로(경구, 비경구 및 기타), 환자 유형(성인, 어린이 및 노인), 최종 사용자(병원, 진료소, 가정 의료 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타) - 업계 동향 및 2029년까지의 예측.

운동실조증 시장

글로벌 운동실조증 시장 분석 및 통찰력

운동 실조증의 유병률이 증가함에 따라 시장 수요가 증가했습니다. 더 나은 건강 서비스를 위한 의료비 지출 증가도 시장 성장에 기여합니다. 이 중요한 기간 동안 주요 시장 참여자들은 제품 출시와 제품 승인에 매우 집중하고 있습니다. 또한 정부와 규제 기관은 급증하는 부상으로 인해 제품 승인을 통해 시장 참여자들을 지원하고 있습니다.

글로벌 운동실조증 시장

글로벌 운동실조증 시장

글로벌 운동 실조증 시장은 시장 참여자의 증가와 첨단 제품의 가용성으로 인해 예측 연도에 성장하고 있습니다. 이와 함께 제조업체는 시장에 새로운 제품을 출시하기 위한 R&D 활동에 참여하고 있습니다. 운동 실조증 치료 분야의 연구 증가와 알코올 및 약물 사용 증가는 시장 성장을 더욱 촉진할 것으로 예상됩니다. 그러나 일부 개발도상국에서 질병을 진단하는 데 어려움이 있고 유전자 검사 시설이 부족하여 예측 기간 동안 글로벌 운동 실조증 시장 성장을 방해할 수 있습니다.

증가하는 의료비 지출과 시장 참여자들의 전략적 이니셔티브는 시장에 치료를 개선할 기회를 제공할 수 있습니다. 그러나 다양한 회사의 약물 및 제품 승인과 제품 리콜과 관련된 몇 가지 엄격한 규칙과 규정이 시장 성장에 도전할 것으로 예상됩니다.

글로벌 운동 실조증 시장은 2022년부터 2029년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년부터 2029년까지의 예측 기간 동안 6.9%의 CAGR로 성장하고 있으며 2021년 22,631.81천 달러에서 2029년까지 36,900.18천 달러에 도달할 것으로 분석합니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020

양적 단위

수익은 천 달러, 가격은 달러로 표시됨

다루는 세그먼트

유형별(척추소뇌성 실조증, 실조증-모세혈관확장증, 발작성 실조증 및 기타(다발계통위축증(MSA))), 제품별(치료 및 진단), 투여 형태(고형, 액체 및 기타), 투여 경로(경구, 비경구 및 기타), 환자 유형(성인, 소아 및 노인), 최종 사용자(병원, 진료소, 가정 의료 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타)

적용 국가

U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Switzerland, Ireland, Russia, Hungary, Austria, Norway, Poland, Turkey, Lithuania, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait, Rest of the Middle East and Africa

Market Players Covered

Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics, Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Apotex Inc., Cipla Inc., Biovista, Design Therapeutics Inc., Reata Pharmaceuticals, Inc., MATRIX BIOMED, Intrabio, Biohaven Pharmaceuticals, Retrotope Inc., Adverum Biotechnologies, Inc., Priory., Sutter Health., Upstream Rehabilitation Inc., Banner Health, Select Medical Corporation, ATI Physical Therapy, among others

Market Definition

Ataxia is a term for a group of disorders that affect coordination, balance, and speech. Anybody part can be affected, but people with ataxia often have difficulties with balance, walking, speaking, swallowing, and tasks requiring a high degree of control, such as writing, eating, and vision. The exact symptoms and their severity vary depending on the type of ataxia a person has.

Ataxia usually results from damage to a part of the brain called the cerebellum, but it can also be caused by damage to other parts of the nervous system. This damage can be part of an underlying condition such as MS (multiple sclerosis) or can be caused by a head injury, lack of oxygen to the brain, or long-term, excessive alcohol consumption. Hereditary ataxia is caused by a faulty gene passed on by family members who may or may not be affected.

Global Ataxia Market Dynamics

Drivers

  • Increasing prevalence and incidence of ataxia

Ataxia is the term for a group of neurological diseases related to the nervous system that affects movement and coordination. People with ataxia often have trouble with balance, coordination, swallowing, and speech. Ataxia usually develops due to damage to a part of the brain, which is the cerebellum that coordinates movement. It is a rare disease, and its incidences are very prevalent globally. The disease has been widely recognized as a major clinical problem worldwide, carrying high morbidity and mortality burden. Hence, increasing prevalence and incident rates of ataxia affecting different age groups drive the global ataxia market.

  • Rapid research in the field of ataxia therapeutics

There is an enormous range of risk factors being reported for ataxia. Hence, to reduce the risk factors and symptoms associated with it, various research is going on in the field of ataxia treatments. Some government funding has also been initiated for the treatment of various types of ataxia in the market. Various rapid research in the field of ataxia therapeutics may help drive the market over the forecasted period and anticipate the major growth in the research and development for the same.

  • Rise in alcohol and drug usage

Rising alcohol and drug usage can lead to vitamin B-12, vitamin E, and thiamine deficiency. The lack of these nutrients in the body is considered to be a major cause of ataxia. A shortage of vitamin E in the body can lead to neurological problems, such as difficulty coordinating movements (ataxia) and speech (dysarthria), loss of reflexes in the legs (lower limb areflexia), and a loss of sensation in the extremities (peripheral neuropathy) this then leads to the various types ataxia. The rising number of people and youth consuming excessive alcohol and drugs also increases the chance of being affected by various types of ataxia. This is expected to act as a driver for the growth of the global ataxia market.

글로벌 운동실조증 시장

Opportunities

  • Rising healthcare expenditure

Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, the government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for ataxia as the disorder has been highly prevalent in recent years.

Restraints/Challenges

However, the difficulty in diagnosing the disease and lack of genetic testing facilities in some of the developing countries will impede the growth rate of the global ataxia market. Additionally, stringent rules and regulations will further challenge the forecast period's market.

This global ataxia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global ataxia market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.

Post COVID-19 Impact on the Global Ataxia Market

COVID-19는 시장에 긍정적인 영향을 미쳤습니다. 팬데믹 동안의 봉쇄와 격리는 질병 관리와 약물 복용을 복잡하게 만듭니다. 따라서 다양한 치료제가 전 세계 인구에서 널리 증가했습니다. 따라서 팬데믹은 이 시장에 긍정적인 영향을 미쳤습니다.

최근 개발

  • 2022년 11월, Pfizer Inc.는 회사가 Arena Pharmaceuticals 인수를 완료했다고 발표했습니다. 이 회사는 여러 면역 염증성 질환을 치료하기 위한 혁신적인 잠재적 치료법을 개발하는 임상 단계 회사입니다. 이를 통해 회사는 이 인수를 통해 제품 포트폴리오를 늘릴 수 있었습니다.

글로벌 운동실조증 시장 범위

글로벌 운동 실조증 시장은 유형, 제품, 투여 형태, 투여 경로, 환자 유형, 최종 사용자 및 유통 채널로 세분화됩니다. 이러한 세그먼트 간의 성장은 산업의 빈약한 성장 세그먼트를 분석하고 사용자에게 핵심 시장 응용 프로그램을 식별하기 위한 전략적 결정을 내릴 수 있는 귀중한 시장 개요와 시장 통찰력을 제공하는 데 도움이 됩니다.

유형

  • 척추소뇌성 실조증
  • 운동실조-모세혈관확장증
  • 에피소드성 운동 실조증
  • 기타(다발계통위축증(MSA))

전 세계 운동실조증 시장은 유형을 기준으로 척추소뇌성 운동실조증, 운동실조-모세혈관확장증, 간헐성 운동실조증 및 기타(다발계통위축증(MSA))로 구분됩니다.

제품

  • 진단
  • 치료

글로벌 운동실조증 시장은 제품을 기준으로 치료와 진단으로 구분됩니다.

투여 형태

  • 단단한
  • 액체
  • 기타

글로벌 운동실조증 시장은 투여 형태를 기준으로 고체, 액체 및 기타로 구분됩니다.

투여 경로

  • 경구     
  • 비경구적
  • 기타

투여 경로를 기준으로 볼 때, 글로벌 운동실조증 시장은 경구, 비경구 및 기타로 구분됩니다.

환자 유형

  • 성인
  • 어린이
  • 노인

환자 유형을 기준으로 글로벌 운동실조증 시장은 성인, 소아, 노인으로 구분됩니다.

최종 사용자

최종 사용자를 기준으로 글로벌 운동실조 시장은 병원, 진료소, 가정 건강 관리 및 기타로 구분됩니다.

유통 채널

  • 직접 입찰
  • 소매 판매
  • 기타

글로벌 운동실조증 시장

글로벌 운동실조증 시장은 유통 채널을 기준으로 직접 입찰, 소매 판매 및 기타로 구분됩니다.

글로벌 운동실조증 시장 지역 분석/통찰력                  

글로벌 운동실조 시장을 분석하고, 위에 언급된 대로 국가, 유형, 제품, 투여 형태, 투여 경로, 환자 유형, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

글로벌 운동실조 시장에서 다루는 주요 국가로는 미국, 캐나다, 멕시코, 독일, 프랑스, ​​영국, 이탈리아, 스페인, 네덜란드, 스위스, 아일랜드, 러시아, 헝가리, 오스트리아, 노르웨이, 폴란드, 터키, 리투아니아, 유럽의 기타 국가, 중국, 일본, 인도, 한국, 호주, 싱가포르, 태국, 말레이시아, 인도네시아, 필리핀, 베트남, 아시아 태평양의 기타 국가, 남아프리카공화국, 사우디 아라비아, UAE, 이집트, 이스라엘, 쿠웨이트, 중동 및 아프리카의 기타 국가가 있습니다.

미국, 독일, 중국이 시장을 지배할 것으로 예상되는데, 이 지역의 인구에서 운동 실조증이 많이 나타나며, 시장 점유율과 시장 수익 측면에서 글로벌 운동 실조증 시장을 지배하고 있으며 예측 기간 동안 지배력을 계속 확대할 것입니다. 이는 의료비 지출이 증가하고 있고, 빠른 연구 개발로 시장이 활성화되고 있기 때문입니다.

글로벌 운동실조증 시장

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규정의 변화를 제공합니다. 신규 및 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 국내 및 국내 브랜드와의 치열한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 글로벌 운동 실조증 시장 점유율 분석

글로벌 운동 실조증 시장 경쟁 구도는 경쟁자들의 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 제공된 위의 데이터 포인트는 회사의 글로벌 운동 실조증 시장에 대한 초점과만 관련이 있습니다.

글로벌 운동실조 시장의 주요 기업으로는 Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics, Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Apotex Inc., Cipla Inc., Biovista, Design Therapeutics Inc., Reata Pharmaceuticals, Inc., MATRIX BIOMED, ​​Intrabio, Biohaven Pharmaceuticals, Retrotope Inc., Adverum Biotechnologies, Inc., Priory., Sutter Health., Upstream Rehabilitation Inc., Banner Health, Select Medical Corporation, ATI Physical Therapy 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.

SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

Sample Image Click on image to enlarge
  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL ATAXIA MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

4.3 EPIDEMIOLOGY

5 PIPELINE ANALYSIS

6 GLOBAL ATAXIA MARKET: REGULATORY SCENARIO

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE AND INCIDENCES OF ATAXIA

7.1.2 RAPID RESEARCH IN FIELD OF ATAXIA THERAPEUTICS

7.1.3 RISE IN ALCOHOL AND DRUG USAGE

7.1.4 GROWING NUMBER OF INCIDENCES OF AUTO-IMMUNE DISEASE

 

7.2 RESTRAINTS

7.2.1 DIFFICULTY IN DIAGNOSIS OF DISEASE

7.2.2 LACK OF GENETIC TESTING IN DEVELOPING COUNTRIES

7.3 OPPORTUNITIES

7.3.1 RISING HEALTHCARE EXPENDITURE

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.4 CHALLENGES

7.4.1 STRINGENT RULES AND REGULATIONS

7.4.2 PRODUCT RECALL

8 GLOBAL ATAXIA MARKET, BY TYPE

8.1 OVERVIEW

8.2 SPINOCEREBELLAR ATAXIAS

8.2.1 TYPE 3

8.2.2 TYPE 2

8.2.3 TYPE 1

8.2.4 OTHERS

8.3 ATAXIA-TELANGIECTASIA

8.4 EPISODIC ATAXIA

8.5 OTHERS (MULTIPLE SYSTEM ATROPHY (MSA))

9 GLOBAL ATAXIA MARKET, BY PRODUCT

9.1 OVERVIEW

9.2 TREATMENT

9.2.1 PHARMACOTHERAPY

9.2.1.1 STIFFNESS/SPASTICITY

9.2.1.1.1 GABAPENTIN

9.2.1.1.2 LEVODOPA

9.2.1.1.3 OTHERS

9.2.1.2 GAIT AND TREMORS

9.2.1.2.1 VARENICLINE

9.2.1.2.2 RILUZOLE

9.2.1.2.3 AMANTADINE

9.2.1.2.4 OTHERS

9.2.1.3 ANTI-OXIDANTS

9.2.1.3.1 N‐ACETYLCYSTEINE

9.2.1.3.2 SELEGILINE

9.2.1.3.3 DEHYDROEPIANDROSTERONE

9.2.1.3.4 VITAMIN E

 

9.2.1.4 NON ANTI-OXIDANTS

9.2.1.4.1 ERYTHROPOIETIN

9.2.1.4.2 DEFERIPRONE

9.2.1.4.3 RESVERATROL

9.2.1.4.4 HISTONE DEACETYLASE INHIBITORS

9.2.1.5 ANTI-ARRHYTHMIC AGENTS

9.2.1.5.1 AMIODARONE

9.2.1.5.2 PROPAFENONE

9.2.1.5.3 FLECAINIDE

9.2.1.5.4 IBUTILIDE

9.2.1.6 ANTI-CARDIAC FAILURE

9.2.1.6.1 BENAZEPRIL

9.2.1.6.2 LISINOPRIL

9.2.1.6.3 CAPTOPRIL

9.2.1.6.4 ENALAPRIL

9.2.1.6.5 FOSINOPRIL

9.2.1.6.6 MOEXIPRIL

9.2.1.6.7 OTHERS

9.2.1.7 ORAL HYPOGLYCEMIC THERAPEUTICS

9.2.1.7.1 BIGUANIDES (METFORMIN)

9.2.1.7.2 SULFONYLUREAS

9.2.1.7.2.1 GLIPIZIDE

9.2.1.7.2.2 GLIMEPIRIDE

9.2.1.7.2.3 GLYBURIDE

9.2.1.7.2.4 OTHERS

9.2.1.7.3 THIAZOLIDINEDIONES

9.2.1.7.4 MEGLITINIDES

9.2.2 LIFESTYLE THERAPY

9.2.2.1 PHYSICAL THERAPY

9.2.2.2 SPEECH THERAPY

9.2.2.3 PALLIATIVE CARE

9.2.2.4 OTHERS

9.2.3 SUPPORTIVE DEVICES

9.2.3.1 WALKING AIDS

9.2.3.2 WHEELCHAIRS

9.2.3.3 OTHERS

 

9.3 DIAGNOSTICS

9.3.1 IMAGING TEST

9.3.1.1 MRI SCAN

9.3.1.2 OTHERS

9.3.2 BLOOD TEST

9.3.3 GENETIC TESTING

10 GLOBAL ATAXIA MARKET, BY DOSAGE FORM

10.1 OVERVIEW

10.2 SOLID

10.2.1 TABLETS

10.2.2 CAPSULES

10.2.3 OTHERS

10.3 LIQUIDS

10.3.1 INJECTION

10.3.2 SOLUTIONS

10.3.3 OTHERS

10.4 OTHERS

11 GLOBAL ATAXIA MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.3 PARENTERAL

11.4 OTHERS

12 GLOBAL ATAXIA MARKET, BY PATIENT TYPE

12.1 OVERVIEW

12.2 ADULT

12.2.1 MALE

12.2.2 FEMALE

12.3 CHILD

12.4 GERIATRIC

13 GLOBAL ATAXIA MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 CLINICS

13.4 HOME HEALTHCARE

13.5 OTHERS

 

14 GLOBAL ATAXIA MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 RETAIL SALES

14.3.1 HOSPITAL PHARMACY

14.3.2 RETAIL SHOP

14.3.3 ONLINE PHARMACY

14.4 OTHERS

15 GLOBAL ATAXIA MARKET, BY GEOGRAPHY

15.1 OVERVIEW

15.2 NORTH AMERICA

15.2.1 U.S.

15.2.2 CANADA

15.2.3 MEXICO

15.3 EUROPE

15.3.1 GERMANY

15.3.2 U.K.

15.3.3 FRANCE

15.3.4 ITALY

15.3.5 SPAIN

15.3.6 SWITZERLAND

15.3.7 NETHERLANDS

15.3.8 IRELAND

15.3.9 RUSSIA

15.3.10 HUNGARY

15.3.11 AUSTRIA

15.3.12 NORWAY

15.3.13 POLAND

15.3.14 TURKEY

15.3.15 LITHUANIA

15.3.16 REST OF EUROPE

 

15.4 ASIA-PACIFIC

15.4.1 CHINA

15.4.2 JAPAN

15.4.3 INDIA

15.4.4 SOUTH KOREA

15.4.5 AUSTRALIA

15.4.6 SINGAPORE

15.4.7 THAILAND

15.4.8 MALAYSIA

15.4.9 INDONESIA

15.4.10 PHILIPPINES

15.4.11 VIETNAM

15.4.12 RESTF OF ASIA-PACIFIC

15.5 SOUTH AMERICA

15.5.1 BRAZIL

15.5.2 ARGENTINA

15.5.3 PERU

15.5.4 RESTF OF SOUTH AMERICA

15.6 MIDDLE EAST AND AFRICA

15.6.1 SOUTH AFRICA

15.6.2 SAUDI ARABIA

15.6.3 U.A.E

15.6.4 ISRAEL

15.6.5 EGYPT

15.6.6 KUWAIT

15.6.7 REST OF MIDDLE EAST AND AFRICA

16 GLOBAL ATAXIA MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: GLOBAL

16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

16.3 COMPANY SHARE ANALYSIS: EUROPE

16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT ANALYSIS

 

18 COMPANY PROFILE

18.1 SELECT MEDICAL CORPORATION

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 PFIZER INC.

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 NOVARTIS AG

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 AMNEAL PHARMACEUTICALS LLC.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLI

18.4.5 RECENT DEVELOPMENT

18.5 UPSTREAM REHABILITATION INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 COMPANY SHARE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.6 PRIORY

18.6.1 COMPANY SNAPSHOT

18.6.2 COMPANY SHARE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 ACORDA THERAPEUTICS, INC.

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS

18.8 ADVERUM BIOTECHNOLOGIES, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 APOTEX INC.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 ATI PHYSICAL THERAPY

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 AUROBINDO PHARMA

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 BANNER HEALTH

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENT

18.13 BIOHAVEN PHARMACEUTICALS

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENTS

18.14 BIOVISTA

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 CIPLA INC.

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 DESIGN THERAPEUTICS, INC.

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

 

18.17 INTRABIO

18.17.1 COMPANY SNAPSHOT

18.17.2 PRODUCT PORTFOLIO

18.17.3 RECENT DEVELOPMENT

18.18 LUPIN.

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENTS

18.19 MATRIX BIOMED

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENT

18.2 MERCK KGAA

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENTS

18.21 REATA PHARMACEUTICALS, INC.

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENT

18.22 RETROTOPE INC.

18.22.1 COMPANY SNAPSHOT

18.22.2 PRODUCT PORTFOLIO

18.22.3 RECENT DEVELOPMENT

18.23 SANOFI

18.23.1 COMPANY SNAPSHOT

18.23.2 REVENUE ANALYSIS

18.23.3 PRODUCT PORTFOLIO

18.23.4 RECENT DEVELOPMENT

18.24 SUN PHARMACEUTICAL INDUSTRIES LTD.

18.24.1 COMPANY SNAPSHOT

18.24.2 REVENUE ANALYSIS

18.24.3 PRODUCT PORTFOLIO

18.24.4 RECENT DEVELOPMENT

18.25 SUTTER HEALTH

18.25.1 COMPANY SNAPSHOT

18.25.2 PRODUCT PORTFOLIO

18.25.3 RECENT DEVELOPMENTS

18.26 TEVA PHARMACEUTICAL INDUSTRIES LTD.

18.26.1 COMPANY SNAPSHOT

18.26.2 REVENUE ANALYSIS

18.26.3 PRODUCT PORTFOLIO

18.26.4 RECENT DEVELOPMENT

18.27 VIATRIS INC.

18.27.1 COMPANY SNAPSHOT

18.27.2 REVENUE ANALYSIS

18.27.3 PRODUCT PORTFOLIO

18.27.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

표 목록

TABLE 1  GLOBAL ATAXIA MARKET: PIPELINE ANALYSIS

TABLE 2  GLOBAL ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 3  GLOBAL SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4  GLOBAL SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 5  GLOBAL ATAXIA-TELANGIECTASIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 6  GLOBAL EPISODIC ATAXIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7  GLOBAL OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 8  GLOBAL ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 9  GLOBAL TREATMENT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 10  GLOBAL TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 11  GLOBAL PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 12  GLOBAL STIFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 13  GLOBAL GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 14  GLOBAL ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 15  GLOBAL NON ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 16  GLOBAL ANTI- ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 17  GLOBAL ANTI- CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 18  GLOBAL ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 19  GLOBAL SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 20  GLOBAL LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 21  GLOBAL SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 22  GLOBAL DIAGNOSTICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23  GLOBAL DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 24  GLOBAL IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 25  GLOBAL ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 26  GLOBAL SOLID IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 27  GLOBAL SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 28  GLOBAL LIQUIDS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 29  GLOBAL LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 30  GLOBAL OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31  GLOBAL ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 32  GLOBAL ORAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33  GLOBAL PARENTERAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 34  GLOBAL OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35  GLOBAL ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 36  GLOBAL ADULT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37  GLOBAL ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 38  GLOBAL CHILD IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 39  GLOBAL GERIATRIC IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40  GLOBAL ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 41  GLOBAL HOSPITAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42  GLOBAL CLINICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 43  GLOBAL HOME HEALTHCARE IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 44  GLOBAL OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 45  GLOBAL ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 46  GLOBAL DIRECT TENDER IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 47  GLOBAL RETAIL SALES IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 48  GLOBAL RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 49  GLOBAL OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 50  GLOBAL ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 51  NORTH AMERICA ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 52  NORTH AMERICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 53  NORTH AMERICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 54  NORTH AMERICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 55  NORTH AMERICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 56  NORTH AMERICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 57  NORTH AMERICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 58  NORTH AMERICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 59  NORTH AMERICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 60  NORTH AMERICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 61  NORTH AMERICA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 62  NORTH ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 63  NORTH AMERICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 64  NORTH AMERICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 65  NORTH AMERICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 66  NORTH AMERICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 67  NORTH AMERICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 68  NORTH AMERICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 69  NORTH AMERICA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 70  NORTH AMERICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 71  NORTH AMERICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 72  NORTH AMERICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 73  NORTH AMERICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 74  NORTH AMERICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 75  NORTH AMERICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 76  NORTH AMERICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 77  NORTH AMERICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 78  U.S. ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 79  U.S. SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 80  U.S. ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 81  U.S. TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 82  U.S. PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 83  U.S. STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 84  U.S. GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 85  U.S. ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 86  U.S. NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 87  U.S. ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 88  U.S. ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 89  U.S. ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 90  U.S. SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 91  U.S. LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 92  U.S. SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 93  U.S. DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 94  U.S. IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 95  U.S. IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 96  U.S. SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 97  U.S. LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 98  U.S. ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 99  U.S. ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 100  U.S. ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 101  U.S. ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 102  U.S. ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 103  U.S. RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 104  CANADA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 105  CANADA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 106  CANADA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 107  CANADA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 108  CANADA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 109  CANADA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 110  CANADA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 111  CANADA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 112  CANADA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 113  CANADA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 114  CANADA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 115  CANADA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 116  CANADA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 117  CANADA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 118  CANADA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 119  CANADA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 120  CANADA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 121  CANADA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 122  CANADA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 123  CANADA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 124  CANADA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 125  CANADA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 126  CANADA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 127  CANADA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 128  CANADA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 129  CANADA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 130  MEXICO ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 131  MEXICO SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 132  MEXICO ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 133  MEXICO TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 134  MEXICO PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 135  MEXICO STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 136  MEXICO GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 137  MEXICO ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 138  MEXICO NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 139  MEXICO ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 140  MEXICO ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 141  MEXICO ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 142  MEXICO SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 143  MEXICO LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 144  MEXICO SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 145  MEXICO DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 146  MEXICO IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 147  \MEXICO IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 148  MEXICO SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 149  MEXICO LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 150  MEXICO ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 151  MEXICO ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 152  MEXICO ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 153  MEXICO ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 154  MEXICO ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 155  MEXICO RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 156  EUROPE ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 157  EUROPE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 158  EUROPE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 159  EUROPE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 160  EUROPE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 161  EUROPE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 162  EUROPE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 163  EUROPE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 164  EUROPE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 165  EUROPE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 166  EUROPE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 167  EUROPE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 168  EUROPE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 169  EUROPE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 170  EUROPE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 171  EUROPE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 172  EUROPE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 173  EUROPE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 174  EUROPE ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 175  EUROPE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 176  EUROPE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 177  EUROPE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 178  EUROPE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 179  EUROPE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 180  EUROPE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 181  EUROPE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 182  EUROPE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 183  GERMANY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 184  GERMANY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 185  GERMANY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 186  GERMANY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 187  GERMANY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 188  GERMANY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 189  GERMANY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 190  GERMANY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 191  GERMANY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 192  GERMANY ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 193  GERMANY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 194  GERMANY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 195  GERMANY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 196  GERMANY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 197  GERMANY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 198  GERMANY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 199  GERMANY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 200  GERMANY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 201  GERMANY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 202  GERMANY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 203  GERMANY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 204  GERMANY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 205  GERMANY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 206  GERMANY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 207  GERMANY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 208  GERMANY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 209  U.K. ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 210  U.K. SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 211  U.K. ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 212  U.K. TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 213  U.K. PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 214  U.K. STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 215  U.K. GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 216  U.K. ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 217  U.K. NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 218  U.K. ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 219  U.K. ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 220  U.K. ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 221  U.K. SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 222  U.K. LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 223  U.K. SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 224  U.K. DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 225  U.K. IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 226  U.K. ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 227  U.K. SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 228  U.K. LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 229  U.K. ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 230  U.K. ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 231  U.K. ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 232  U.K. ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 233  U.K. ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 234  U.K. RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 235  FRANCE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 236  FRANCE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 237  FRANCE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 238  FRANCE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 239  FRANCE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 240  FRANCE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 241  FRANCE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 242  FRANCE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 243  FRANCE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 244  FRANCE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 245  FRANCE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 246  FRANCE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 247  FRANCE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 248  FRANCE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 249  FRANCE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 250  FRANCE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 251  FRANCE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 252  FRANCE ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 253  FRANCE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 254  FRANCE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 255  FRANCE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 256  FRANCE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 257  FRANCE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 258  FRANCE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 259  FRANCE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 260  FRANCE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 261  ITALY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 262  ITALY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 263  ITALY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 264  ITALY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 265  ITALY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 266  ITALY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 267  ITALY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 268  ITALY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 269  ITALY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 270  ITALY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 271  ITALY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 272  ITALY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 273  ITALY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 274  ITALY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 275  ITALY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 276  ITALY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 277  ITALY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 278  ITALY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 279  ITALY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 280  ITALY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 281  ITALY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 282  ITALY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 283  ITALY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 284  ITALY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 285  ITALY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 286  ITALY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 287  SPAIN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 288  SPAIN SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 289  SPAIN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 290  SPAIN TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 291  SPAIN PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 292  SPAIN STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 293  SPAIN GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 294  SPAIN ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 295  SPAIN NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 296  SPAIN ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 297  SPAIN ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 298  SPAIN ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 299  SPAIN SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 300  SPAIN LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 301  SPAIN SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 302  SPAIN DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 303  SPAIN IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 304  SPAIN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 305  SPAIN SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 306  SPAIN LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 307  SPAIN ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 308  SPAIN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 309  SPAIN ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 310  SPAIN ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 311  SPAIN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 312  SPAIN RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 313  SWITZERLAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 314  SWITZERLAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 315  SWITZERLAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 316  SWITZERLAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 317  SWITZERLAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 318  SWITZERLAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 319  SWITZERLAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 320  SWITZERLAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 321  SWITZERLAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 322  SWITZERLAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 323  SWITZERLAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 324  SWITZERLAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 325  SWITZERLAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 326  SWITZERLAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 327  SWITZERLAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 328  SWITZERLAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 329  SWITZERLAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 330  SWITZERLAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 331  SWITZERLAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 332  SWITZERLAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 333  SWITZERLAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 334  SWITZERLAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 335  SWITZERLAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 336  SWITZERLAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 337  SWITZERLAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 338  SWITZERLAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 339  NETHERLANDS ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 340  NETHERLANDS SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 341  NETHERLANDS ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 342  NETHERLANDS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 343  NETHERLANDS PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 344  NETHERLANDS STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 345  NETHERLANDS GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 346  NETHERLANDS ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 347  NETHERLANDS NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 348  NETHERLANDS ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 349  NETHERLANDS ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 350  NETHERLANDS ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 351  NETHERLANDS SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 352  NETHERLANDS LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 353  NETHERLANDS SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 354  NETHERLANDS DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 355  NETHERLANDS IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 356  NETHERLANDS ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 357  NETHERLANDS SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 358  NETHERLANDS LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 359  NETHERLANDS ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 360  NETHERLANDS ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 361  NETHERLANDS ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 362  NETHERLANDS ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 363  NETHERLANDS ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 364  NETHERLANDS RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 365  IRELAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 366  IRELAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 367  IRELAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 368  IRELAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 369  IRELAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 370  IRELAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 371  IRELAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 372  IRELAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 373  IRELAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 374  IRELAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 375  IRELAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 376  IRELAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 377  IRELAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 378  IRELAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 379  IRELAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 380  IRELAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 381  IRELAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 382  IRELAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 383  IRELAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 384  IRELAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 385  IRELAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 386  IRELAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 387  IRELAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 388  IRELAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 389  IRELAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 390  IRELAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 391  RUSSIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 392  RUSSIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 393  RUSSIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 394  RUSSIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 395  RUSSIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 396  RUSSIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 397  RUSSIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 398  RUSSIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 399  RUSSIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 400  RUSSIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 401  RUSSIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 402  RUSSIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 403  RUSSIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 404  RUSSIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 405  RUSSIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 406  RUSSIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 407  RUSSIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 408  RUSSIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 409  RUSSIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 410  RUSSIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 411  RUSSIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 412  RUSSIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 413  RUSSIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 414  RUSSIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 415  RUSSIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 416  RUSSIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 417  HUNGARY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 418  HUNGARY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 419  HUNGARY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 420  HUNGARY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 421  HUNGARY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 422  HUNGARY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 423  HUNGARY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 424  HUNGARY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 425  HUNGARY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 426  HUNGARY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 427  HUNGARY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 428  HUNGARY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 429  HUNGARY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 430  HUNGARY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 431  HUNGARY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 432  HUNGARY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 433  HUNGARY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 434  HUNGARY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 435  HUNGARY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 436  HUNGARY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 437  HUNGARY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 438  HUNGARY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 439  HUNGARY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 440  HUNGARY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 441  HUNGARY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 442  HUNGARY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 443  AUSTRIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 444  AUSTRIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 445  AUSTRIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 446  AUSTRIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 447  AUSTRIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 448  AUSTRIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 449  AUSTRIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 450  AUSTRIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 451  AUSTRIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 452  AUSTRIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 453  AUSTRIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 454  AUSTRIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 455  AUSTRIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 456  AUSTRIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 457  AUSTRIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 458  AUSTRIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 459  AUSTRIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 460  AUSTRIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 461  AUSTRIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 462  AUSTRIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 463  AUSTRIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 464  AUSTRIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 465  AUSTRIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 466  AUSTRIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 467  AUSTRIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 468  AUSTRIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 469  NORWAY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 470  NORWAY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 471  NORWAY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 472  NORWAY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 473  NORWAY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 474  NORWAY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 475  NORWAY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 476  NORWAY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 477  NORWAY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 478  NORWAY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 479  NORWAY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 480  NORWAY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 481  NORWAY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 482  NORWAY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 483  NORWAY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 484  NORWAY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 485  NORWAY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 486  NORWAY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 487  NORWAY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 488  NORWAY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 489  NORWAY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 490  NORWAY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 491  NORWAY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 492  NORWAY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 493  NORWAY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 494  NORWAY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 495  POLAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 496  POLAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 497  POLAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 498  POLAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 499  POLAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 500  POLAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 501  POLAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 502  POLAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 503  POLAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 504  POLAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 505  POLAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 506  POLAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 507  POLAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 508  POLAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 509  POLAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 510  POLAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 511  POLAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 512  POLAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 513  POLAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 514  POLAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 515  POLAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 516  POLAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 517  POLAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 518  POLAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 519  POLAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 520  POLAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 521  TURKEY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 522  TURKEY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 523  TURKEY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 524  TURKEY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 525  TURKEY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 526  TURKEY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 527  TURKEY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 528  TURKEY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 529  TURKEY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 530  TURKEY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 531  TURKEY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 532  TURKEY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 533  TURKEY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 534  TURKEY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 535  TURKEY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 536  TURKEY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 537  TURKEY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 538  TURKEY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 539  TURKEY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 540  TURKEY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 541  TURKEY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 542  TURKEY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 543  TURKEY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 544  TURKEY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 545  TURKEY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 546  TURKEY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 547  LITHUANIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 548  LITHUANIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 549  LITHUANIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 550  LITHUANIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 551  LITHUANIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 552  LITHUANIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 553  LITHUANIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 554  LITHUANIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 555  LITHUANIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 556  LITHUANIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 557  LITHUANIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 558  LITHUANIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 559  LITHUANIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 560  LITHUANIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 561  LITHUANIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 562  LITHUANIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 563  LITHUANIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 564  LITHUANIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 565  LITHUANIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 566  LITHUANIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 567  LITHUANIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 568  LITHUANIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 569  LITHUANIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 570  LITHUANIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 571  LITHUANIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 572  LITHUANIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 573  REST OF EUROPE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 574  ASIA-PACIFIC ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 575  ASIA-PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 576  ASIA-PACIFIC SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 577  ASIA-PACIFIC ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 578  ASIA-PACIFIC TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 579  ASIA-PACIFIC PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 580  ASIA-PACIFIC STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 581  ASIA-PACIFIC GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 582  ASIA-PACIFIC ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 583  ASIA-PACIFIC NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 584  ASIA-PACIFIC ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 585  ASIA-PACIFIC ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 586  ASIA-PACIFIC ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 587  ASIA-PACIFIC SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 588  ASIA-PACIFIC LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 589  ASIA-PACIFIC SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 590  ASIA-PACIFIC DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 591  ASIA-PACIFIC IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 592  ASIA-PACIFIC IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 593  ASIA-PACIFIC SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 594  ASIA-PACIFIC LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 595  ASIA-PACIFIC ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 596  ASIA-PACIFIC ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 597  ASIA-PACIFIC ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 598  ASIA-PACIFIC ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 599  ASIA-PACIFIC ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 600  ASIA-PACIFIC RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 601  CHINA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 602  CHINA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 603  CHINA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 604  CHINA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 605  CHINA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 606  CHINA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 607  CHINA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 608  CHINA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 609  CHINA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 610  CHINA ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 611  CHINA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 612  CHINA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 613  CHINA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 614  CHINA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 615  CHINA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 616  CHINA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 617  CHINA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 618  CHINA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 619  CHINA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 620  CHINA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 621  CHINA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 622  CHINA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 623  CHINA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 624  CHINA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 625  CHINA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 626  CHINA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 627  JAPAN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 628  JAPAN SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 629  JAPAN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 630  JAPAN TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 631  JAPAN PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 632  JAPAN STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 633  JAPAN GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 634  JAPAN ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 635  JAPAN NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 636  JAPAN ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 637  JAPAN ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 638  JAPAN ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 639  JAPAN SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 640  JAPAN LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 641  JAPAN SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 642  JAPAN DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 643  JAPAN IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 644  JAPAN IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 645  JAPAN SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 646  JAPAN LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 647  JAPAN ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 648  JAPAN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 649  JAPAN ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 650  JAPAN ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 651  JAPAN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 652  JAPAN RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 653  INDIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 654  INDIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 655  INDIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 656  INDIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 657  INDIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 658  INDIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 659  INDIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 660  INDIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 661  INDIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 662  INDIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 663  INDIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 664  INDIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 665  INDIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 666  INDIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 667  INDIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 668  INDIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 669  INDIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 670  INDIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 671  INDIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 672  INDIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 673  INDIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 674  INDIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 675  INDIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 676  INDIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 677  INDIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 678  INDIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 679  SOUTH KOREA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 680  SOUTH KOREA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 681  SOUTH KOREA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 682  SOUTH KOREA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 683  SOUTH KOREA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 684  SOUTH KOREA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 685  SOUTH KOREA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 686  SOUTH KOREA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 687  SOUTH KOREA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 688  SOUTH KOREA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 689  SOUTH KOREA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 690  SOUTH KOREA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 691  SOUTH KOREA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 692  SOUTH KOREA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 693  SOUTH KOREA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 694  SOUTH KOREA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 695  SOUTH KOREA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 696  SOUTH KOREA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 697  SOUTH KOREA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 698  SOUTH KOREA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 699  SOUTH KOREA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 700  SOUTH KOREA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 701  SOUTH KOREA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 702  SOUTH KOREA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 703  SOUTH KOREA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 704  SOUTH KOREA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 705  AUSTRALIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 706  AUSTRALIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 707  AUSTRALIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 708  AUSTRALIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 709  AUSTRALIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 710  AUSTRALIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 711  AUSTRALIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 712  AUSTRALIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 713  AUSTRALIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 714  AUSTRALIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 715  AUSTRALIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 716  AUSTRALIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 717  AUSTRALIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 718  AUSTRALIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 719  AUSTRALIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 720  AUSTRALIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 721  AUSTRALIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 722  AUSTRALIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 723  AUSTRALIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 724  AUSTRALIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 725  AUSTRALIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 726  AUSTRALIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 727  AUSTRALIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 728  AUSTRALIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 729  AUSTRALIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 730  AUSTRALIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 731  SINGAPORE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 732  SINGAPORE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 733  SINGAPORE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 734  SINGAPORE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 735  SINGAPORE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 736  SINGAPORE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 737  SINGAPORE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 738  SINGAPORE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 739  SINGAPORE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 740  SINGAPORE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 741  SINGAPORE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 742  SINGAPORE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 743  SINGAPORE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 744  SINGAPORE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 745  SINGAPORE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 746  SINGAPORE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 747  SINGAPORE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 748  SINGAPORE IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 749  SINGAPORE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 750  SINGAPORE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 751  SINGAPORE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 752  SINGAPORE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 753  SINGAPORE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 754  SINGAPORE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 755  SINGAPORE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 756  SINGAPORE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 757  THAILAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 758  THAILAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 759  THAILAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 760  THAILAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 761  THAILAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 762  THAILAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 763  THAILAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 764  THAILAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 765  THAILAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 766  THAILAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 767  THAILAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 768  THAILAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 769  THAILAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 770  THAILAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 771  THAILAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 772  THAILAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 773  THAILAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 774  THAILAND IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 775  THAILAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 776  THAILAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 777  THAILAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 778  THAILAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 779  THAILAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 780  THAILAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 781  THAILAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 782  THAILAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 783  MALAYSIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 784  MALAYSIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 785  MALAYSIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 786  MALAYSIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 787  MALAYSIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 788  MALAYSIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 789  MALAYSIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 790  MALAYSIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 791  MALAYSIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 792  MALAYSIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 793  MALAYSIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 794  MALAYSIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 795  MALAYSIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 796  MALAYSIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 797  MALAYSIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 798  MALAYSIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 799  MALAYSIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 800  MALAYSIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 801  MALAYSIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 802  MALAYSIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 803  MALAYSIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 804  MALAYSIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 805  MALAYSIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 806  MALAYSIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 807  MALAYSIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 808  MALAYSIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 809  INDONESIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 810  INDONESIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 811  INDONESIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 812  INDONESIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 813  INDONESIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 814  INDONESIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 815  INDONESIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 816  INDONESIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 817  INDONESIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 818  INDONESIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 819  INDONESIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 820  INDONESIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 821  INDONESIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 822  INDONESIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 823  INDONESIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 824  INDONESIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 825  INDONESIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 826  INDONESIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 827  INDONESIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 828  INDONESIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 829  INDONESIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 830  INDONESIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 831  INDONESIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 832  INDONESIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 833  INDONESIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 834  INDONESIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 835  PHILIPPINES ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 836  PHILIPPINES SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 837  PHILIPPINES ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 838  PHILIPPINES TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 839  PHILIPPINES PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 840  PHILIPPINES STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 841  PHILIPPINES GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 842  PHILIPPINES ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 843  PHILIPPINES NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 844  PHILIPPINES ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 845  PHILIPPINES ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 846  PHILIPPINES ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 847  PHILIPPINES SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 848  PHILIPPINES LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 849  PHILIPPINES SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 850  PHILIPPINES DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 851  PHILIPPINES IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 852  PHILIPPINES IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 853  PHILIPPINES SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 854  PHILIPPINES LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 855  PHILIPPINES ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 856  PHILIPPINES ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 857  PHILIPPINES ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 858  PHILIPPINES ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 859  PHILIPPINES ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 860  PHILIPPINES RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 861  VIETNAM ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 862  VIETNAM SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 863  VIETNAM ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 864  VIETNAM TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 865  VIETNAM PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 866  VIETNAM STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 867  VIETNAM GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 868  VIETNAM ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 869  VIETNAM NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 870  VIETNAM ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 871  VIETNAM ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 872  VIETNAM ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 873  VIETNAM SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 874  VIETNAM LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 875  VIETNAM SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 876  VIETNAM DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 877  VIETNAM IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 878  VIETNAM IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 879  VIETNAM SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 880  VIETNAM LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 881  VIETNAM ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 882  VIETNAM ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 883  VIETNAM ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 884  VIETNAM ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 885  VIETNAM ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 886  VIETNAM RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 887  RESTF OF ASIA-PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 888  SOUTH AMERICA ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 889  SOUTH AMERICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 890  SOUTH AMERICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 891  SOUTH AMERICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 892  SOUTH AMERICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 893  SOUTH AMERICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 894  SOUTH AMERICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 895  SOUTH AMERICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 896  SOUTH AMERICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 897  SOUTH AMERICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 898  SOUTH AMERICA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 899  SOUTH AMERICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 900  SOUTH AMERICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 901  SOUTH AMERICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 902  SOUTH AMERICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 903  SOUTH AMERICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 904  SOUTH AMERICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 905  SOUTH AMERICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 906  SOUTH AMERICA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 907  SOUTH AMERICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 908  SOUTH AMERICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 909  SOUTH AMERICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 910  SOUTH AMERICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 911  SOUTH AMERICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 912  SOUTH AMERICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 913  SOUTH AMERICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 914  SOUTH AMERICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 915  BRAZIL ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 916  BRAZIL SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 917  BRAZIL ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 918  BRAZIL TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 919  BRAZIL PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 920  BRAZIL STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 921  BRAZIL GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 922  BRAZIL ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 923  BRAZIL NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 924  BRAZIL ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 925  BRAZIL ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 926  BRAZIL ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 927  BRAZIL SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 928  BRAZIL LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 929  BRAZIL SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 930  BRAZIL DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 931  BRAZIL IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 932  BRAZIL IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 933  BRAZIL SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 934  BRAZIL LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 935  BRAZIL ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 936  BRAZIL ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 937  BRAZIL ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 938  BRAZIL ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 939  BRAZIL ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 940  BRAZIL RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 941  ARGENTINA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 942  ARGENTINA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 943  ARGENTINA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 944  ARGENTINA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 945  ARGENTINA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 946  ARGENTINA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 947  ARGENTINA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 948  ARGENTINA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 949  ARGENTINA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 950  ARGENTINA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 951  ARGENTINA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 952  ARGENTINA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 953  ARGENTINA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 954  ARGENTINA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 955  ARGENTINA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 956  ARGENTINA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 957  ARGENTINA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 958  ARGENTINA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 959  ARGENTINA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 960  ARGENTINA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 961  ARGENTINA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 962  ARGENTINA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 963  ARGENTINA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 964  ARGENTINA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 965  ARGENTINA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 966  ARGENTINA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 967  PERU ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 968  PERU SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 969  PERU ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 970  PERU TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 971  PERU PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 972  PERU STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 973  PERU GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 974  PERU ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 975  PERU NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 976  PERU ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 977  PERU ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 978  PERU ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 979  PERU SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 980  PERU LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 981  PERU SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 982  PERU DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 983  PERU IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 984  PERU IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 985  PERU SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 986  PERU LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 987  PERU ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 988  PERU ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 989  PERU ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 990  PERU ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 991  PERU ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 992  PERU RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 993  RESTF OF SOUTH AMERICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 994  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 995  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 996  MIDDLE EAST AND AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 997  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 998  MIDDLE EAST AND AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 999  MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1000  MIDDLE EAST AND AFRICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1001  MIDDLE EAST AND AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1002  MIDDLE EAST AND AFRICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1003  MIDDLE EAST AND AFRICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1004  MIDDLE EAST AND AFRICA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1005  MIDDLE EAST AND AFRICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1006  MIDDLE EAST AND AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1007  MIDDLE EAST AND AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1008  MIDDLE EAST AND AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1009  MIDDLE EAST AND AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1010  MIDDLE EAST AND AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1011  MIDDLE EAST AND AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1012  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1013  MIDDLE EAST AND AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1014  MIDDLE EAST AND AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1015  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1016  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1017  MIDDLE EAST AND AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1018  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1019  MIDDLE EAST AND AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1020  MIDDLE EAST AND AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1021  SOUTH AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1022  SOUTH AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1023  SOUTH AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1024  SOUTH AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1025  SOUTH AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1026  SOUTH AFRICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1027  SOUTH AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1028  SOUTH AFRICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1029  SOUTH AFRICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1030  SOUTH AFRICA ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1031  SOUTH AFRICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1032  SOUTH AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1033  SOUTH AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1034  SOUTH AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1035  SOUTH AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1036  SOUTH AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1037  SOUTH AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1038  SOUTH AFRICA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1039  SOUTH AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1040  SOUTH AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1041  SOUTH AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1042  SOUTH AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1043  SOUTH AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1044  SOUTH AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1045  SOUTH AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1046  SOUTH AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1047  SAUDI ARABIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1048  SAUDI ARABIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1049  SAUDI ARABIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1050  SAUDI ARABIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1051  SAUDI ARABIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1052  SAUDI ARABIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1053  SAUDI ARABIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1054  SAUDI ARABIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1055  SAUDI ARABIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1056  SAUDI ARABIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1057  SAUDI ARABIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1058  SAUDI ARABIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1059  SAUDI ARABIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1060  SAUDI ARABIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1061  SAUDI ARABIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1062  SAUDI ARABIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1063  SAUDI ARABIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1064  SAUDI ARABIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1065  SAUDI ARABIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1066  SAUDI ARABIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1067  SAUDI ARABIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1068  SAUDI ARABIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1069  SAUDI ARABIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1070  SAUDI ARABIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1071  SAUDI ARABIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1072  SAUDI ARABIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1073  U.A.E ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1074  U.A.E SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1075  U.A.E ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1076  U.A.E TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1077  U.A.E PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1078  U.A.E STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1079  U.A.E GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1080  U.A.E ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1081  U.A.E NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1082  U.A.E ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1083  U.A.E ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1084  U.A.E ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1085  U.A.E SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1086  U.A.E LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1087  U.A.E SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1088  U.A.E DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1089  U.A.E IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1090  U.A.E IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1091  U.A.E SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1092  U.A.E LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1093  U.A.E ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1094  U.A.E ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1095  U.A.E ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1096  U.A.E ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1097  U.A.E ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1098  U.A.E RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1099  ISRAEL ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1100  ISRAEL SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1101  ISRAEL ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1102  ISRAEL TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1103  ISRAEL PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1104  ISRAEL STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1105  ISRAEL GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1106  ISRAEL ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1107  ISRAEL NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1108  ISRAEL ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1109  ISRAEL ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1110  ISRAEL ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1111  ISRAEL SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1112  ISRAEL LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1113  ISRAEL SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1114  ISRAEL DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1115  ISRAEL IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1116  ISRAEL IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1117  ISRAEL SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1118  ISRAEL LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1119  ISRAEL ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1120  ISRAEL ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1121  ISRAEL ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1122  ISRAEL ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1123  ISRAEL ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1124  ISRAEL RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1125  EGYPT ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1126  EGYPT SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1127  EGYPT ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1128  EGYPT TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1129  EGYPT PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1130  EGYPT STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1131  EGYPT GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1132  EGYPT ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1133  EGYPT NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1134  EGYPT ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1135  EGYPT ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1136  EGYPT ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1137  EGYPT SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1138  EGYPT LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1139  EGYPT SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1140  EGYPT DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1141  EGYPT IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1142  EGYPT IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1143  EGYPT SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1144  EGYPT LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1145  EGYPT ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1146  EGYPT ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1147  EGYPT ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1148  EGYPT ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1149  EGYPT ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1150  EGYPT RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1151  KUWAIT ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1152  KUWAIT SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1153  KUWAIT ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1154  KUWAIT TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1155  KUWAIT PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1156  KUWAIT STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1157  KUWAIT GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1158  KUWAIT ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1159  KUWAIT NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1160  KUWAIT ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1161  KUWAIT ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1162  KUWAIT ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1163  KUWAIT SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1164  KUWAIT LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1165  KUWAIT SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1166  KUWAIT DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1167  KUWAIT IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1168  KUWAIT IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1169  KUWAIT SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1170  KUWAIT LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1171  KUWAIT ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1172  KUWAIT ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1173  KUWAIT ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1174  KUWAIT ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1175  KUWAIT ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1176  KUWAIT RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1177  REST OF MIDDLE EAST AND AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

그림 목록

FIGURE 1  GLOBAL ATAXIA MARKET: SEGMENTATION

FIGURE 2  GLOBAL ATAXIA MARKET: DATA TRIANGULATION

FIGURE 3  GLOBAL ATAXIA MARKET: DROC ANALYSIS

FIGURE 4  GLOBAL ATAXIA MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5  GLOBAL ATAXIA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6  GLOBAL ATAXIA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7  GLOBAL ATAXIA MARKET: DBMR MARKET POSITION GRID

FIGURE 8  GLOBAL ATAXIA MARKET: END USER COVERAGE GRID

FIGURE 9  GLOBAL ATAXIA MARKET: VENDOR SHARE ANALYSIS

FIGURE 10  GLOBAL ATAXIA MARKET: SEGMENTATION

FIGURE 11  RAPID RESEARCH IN FIELD OF ATAXIA THEREPEUTICS IS EXPECTED TO DRIVE THE GLOBAL ATAXIA MARKET IN THE FORECAST PERIOD

FIGURE 12  SPINOCEREBELLAR ATAXIAS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ATAXIA MARKET IN 2022 & 2029

FIGURE 13  NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL ATAXIA MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14  ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL ATAXIA MARKET MANUFACTURERS IN THE FORECAST PERIOD

FIGURE 15  DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL ATAXIA MARKET

FIGURE 16  GLOBAL ATAXIA MARKET: BY TYPE, 2021

FIGURE 17  GLOBAL ATAXIA MARKET: BY TYPE, 2022-2029 (USD THOUSAND)

FIGURE 18  GLOBAL ATAXIA MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 19  GLOBAL ATAXIA MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20  GLOBAL ATAXIA MARKET: BY PRODUCT, 2021

FIGURE 21  GLOBAL ATAXIA MARKET: BY PRODUCT, 2022-2029 (USD THOUSAND)

FIGURE 22  GLOBAL ATAXIA MARKET: BY PRODUCT, CAGR (2022-2029)

FIGURE 23  GLOBAL ATAXIA MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 24  GLOBAL ATAXIA MARKET: BY DOSAGE FORM, 2021

FIGURE 25  GLOBAL ATAXIA MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)

FIGURE 26  GLOBAL ATAXIA MARKET: BY DOSAGE FORM, CAGR (2022-2029)

FIGURE 27  GLOBAL ATAXIA MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 28  GLOBAL ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 29  GLOBAL ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND)

FIGURE 30  GLOBAL ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 31  GLOBAL ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 32  GLOBAL ATAXIA MARKET: BY PATIENT TYPE, 2021

FIGURE 33  GLOBAL ATAXIA MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)

FIGURE 34  GLOBAL ATAXIA MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 35  GLOBAL ATAXIA MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 36  GLOBAL ATAXIA MARKET: BY END USER, 2021

FIGURE 37  GLOBAL ATAXIA MARKET: BY END USER, 2022-2029 (USD THOUSAND)

FIGURE 38  GLOBAL ATAXIA MARKET: BY END USER, CAGR (2022-2029)

FIGURE 39  GLOBAL ATAXIA MARKET: BY END USER, LIFELINE CURVE

FIGURE 40  GLOBAL ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 41  GLOBAL ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)

FIGURE 42  GLOBAL ATAXIA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 43  GLOBAL ATAXIA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44  GLOBAL ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 45  GLOBAL ATAXIA MARKET: BY REGION (2021)

FIGURE 46  GLOBAL ATAXIA MARKET: BY REGION (2022 & 2029)

FIGURE 47  GLOBAL ATAXIA MARKET: BY REGION (2021 & 2029)

FIGURE 48  GLOBAL ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 49  NORTH AMERICA ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 50  NORTH AMERICA ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 51  NORTH AMERICA ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 52  NORTH AMERICA ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 53  NORTH AMERICA ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 54  EUROPE ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 55  EUROPE ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 56  EUROPE ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 57  EUROPE ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 58  EUROPE ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 59  ASIA-PACIFIC ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 60  ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 61  ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 62  ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 63  ASIA-PACIFIC ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 64  SOUTH AMERICA ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 65  SOUTH AMERICA ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 66  SOUTH AMERICA ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 67  SOUTH AMERICA ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 68  SOUTH AMERICA ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 69  MIDDLE EAST AND AFRICA ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 70  MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 71  MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 72  MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 73  MIDDLE EAST AND AFRICA ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 74  GLOBAL ATAXIA MARKET: COMPANY SHARE 2021 (%)

FIGURE 75  NORTH AMERICA ATAXIA MARKET: COMPANY SHARE 2021 (%)

FIGURE 76  EUROPE ATAXIA MARKET: COMPANY SHARE 2021 (%)

FIGURE 77  ASIA-PACIFIC ATAXIA MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The market is segmented based on , By Type (Spinocerebellar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), Product (Treatment and Diagnosis), Dosage Form (Solid, Liquids, and Others), Route of Administration (Oral, Parenteral, and Others), Patient Type (Adult, Child, and Geriatric), End User (Hospital, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2029. .
The Global Ataxia Market size was valued at USD 22631.81 USD Thousand in 2021.
The Global Ataxia Market is projected to grow at a CAGR of 6.9% during the forecast period of 2022 to 2029.
The major players operating in the market include Novartis, Merck, Aurobindo Pharma, Pfizer, Sanofi, Teva Pharmaceutical Industries, Acorda Therapeutics, Viatris, Sun Pharmaceutical Industries, Lupin, Amneal Pharmaceuticals, Apotex, Cipla, Biovista, Design Therapeutics, Reata Pharmaceuticals, MATRIX BIOMED, Intrabio, Biohaven Pharmaceuticals, Retrotope, Adverum Biotechnologies, Priory, Sutter Health, Upstream Rehabilitation, Banner Health, Select Medical Corporation, ATI Physical Therapy.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Switzerland, Ireland, Russia, Hungary, Austria, Norway, Poland, Turkey, Lithuania, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait, Rest of the Middle East and Africa.

관련 페이지 탐색

Banner